MelissaKristenFreyMD

Gynecologic Oncology, Minimally Invasive / Endoscopic Surgery, Urogynecology & Pelvic Reconstructive Surgery

Assistant Professor of Obstetrics and Gynecology in the division of gynecologic oncology at Weill Cornell Medicine

Overview of Dr. Frey

Dr. Melissa Frey is an obstetrician/gynecologist in New York, NY and is affiliated with New York-Presbyterian Hospital and Weill Cornell Medicine. She received her medical degree from Weill Cornell Medicine and has been in practice 8 years. She specializes in gynecologic oncology and cancer genetics.

Office
525 E 68th St
# 122
New York, NY 10065
Book by Phone+1(224) 301-2291

Education & Training

NYU Grossman School of MedicineFellowship, Gynecologic Oncology, 2013 - 2016
New York Presbyterian Hospital (Cornell Campus)Residency, Obstetrics and Gynecology, 2009 - 2013
Weill Cornell MedicineClass of 2009

Certifications & Licensure

NY State Medical License 2013 - 2026
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Clinical Trials

FaCT Trial (Facilitated Cascade Testing Trial) Start of enrollment: 2021 Jul 21
Recruiting
Not Applicable

Publications & Presentations

PubMed

1 citations
Considering screening for hereditary cancer syndromes at the time of obstetrical prenatal carrier screening.
Luiza Perez, Shayan Dioun, Michelle Primiano, Stephanie V Blank, Steven Lipkin
Cancer. 2024-12-15
Cost-effectiveness of BRCA1 with prenatal carrier screening.
Shayan M Dioun, Jason D Wright, Melissa K Frey
American Journal of Obstetrics and Gynecology. 2024-12-11
Bridging Gaps in Cervical Cancer Care: A Web-Based Intervention to Improve Knowledge and Follow-up.
Amita Kulkarni, Muhammad Danyal Ahsan, Taylor LaRosa, Emily Webster, Xiaoyue Ma
Journal of Lower Genital Tract Disease. 2024-12-03

Journal Articles

Prevalence of Nonfounder BRCA1/2 Mutations in Ashkenazi Jewish Patients Presenting for Genetic Testing at a Hereditary Breast and Ovarian Cancer Center
Kevin Holcomb, Rohini V Kopparam, Melissa K Frey, Thomas Caputo, Cancer

Lectures

Multi-parametric FDG PET/MRI as an early predictor of response to neoadjuvant chemotherapy in patients with epithelial ovarian cancer.
2019 ASCO Annual Meeting - 6/1/2019

Authored Content

Articles & IssuesDecember 2018

Press Mentions

What You Should Know About Ovarian Cancer VaccinesNovember 16th, 2024
Faster, Easier, and More Anxiety-Inducing: Are DHTs Harming Patients' Mental Health?February 2nd, 2023
Universal Genetic Testing Is Far from a Reality in Patients with Ovarian CancerJune 8th, 2021
Join now to see all